Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Clinical pharmacology of the anticancer polypeptide neocarzinostatin

Summary

The clinical pharmacology of the anticancer polypeptide neocarzinostatin was studied in 16 patients with disseminated neoplasia using a radioimmunoassay technique. Patients who received 2,400–3,600 U of the drug per square meter BSA by rapid IV infusion had triphasic plasma decay curves. For eight patients with normal hepatic and renal function, neocarzinostatin mean plasma half-lives were 0.14, 0.50, and 7.7h. The mean plasma drug clearance was 32.4 ml/min/m2 and the apparent volume of distribution 19.3l/m2. Two patients with liver dysfunction had shorter terminal plasma half-lives and greater drug clearances, while two with renal disease exhibited prolonged plasma half-lives and reduced drug clearances. The mean cumulative urinary excretion of neocarzinostatin was 69.1% of the administered dose at 72 h in three patients with normal hepatic and renal function. One patient with liver disease excreted 90.4%, while a patient with renal disease excreted only 58.1% of the dose in 24 h. In one patient with marked liver disease, biliary excretion accounted for 0.1% of the administered dose in 72 h. Cerebrospinal fluid concentrations of neocarzinostatin studied in two patients showed a CSF penetration of about 16% the plasma concentration at 1–5 h; concentrations persisted for 19 h in one patient with an Omayha reservoir. Neocarzinostatin was rapidly cleared from the plasma and eliminated in the urine. Dosage reductions of 50% are recommended for patients with impaired renal function, while no reduction or escalated doses could be tolerated by patients with liver disease. The pharmacologic data suggest a continuous IV infusion may be a more toxic but perhaps more effective schedule of administration.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Bhuyan BK, Scheidt LG, Fraser TJ (1972) Cell cycle specificity of antitumor agents. Cancer Res 32:398–407

  2. 2.

    Broughton A, Strong JE (1976) Radioimmunoassay of bleomycin. Cancer Res 36:1418–1421

  3. 3.

    Comis RL, Griffin T, Raso V, Ginsberg S (1977) The clinical pharmacology of Neocarzinostatin. Proc Am Assoc Cancer Res 18:124

  4. 4.

    Griffin TW, Lister TA, Rybak ME, Rosenthal DS, Canellos G, Woodruff R, Oliver KT (1978) Neocarzinostatin (NCS) in patients with acute non-lymphocytic leukemia (ANLL) in relapse. Proc Am Soc Clin Oncol 19:398

  5. 5.

    Hall SW, Valdivieso M, Benjamin RS (1977) Clinical pharmacology of bleomycin by radioimmunoassay. Clin Res 25:407A

  6. 6.

    Hiraki K, Kamimura P, Takahashi I, Nagao T et al. (1973) Neocarzinostatin. A new chemotherapeutic approach to acute leukemia. Nouv Rev Fr Hematol 13:445–452

  7. 7.

    Ishida N, Miyazaki K, Kumagai K, Kikimaru (1965) Neocarzinostatin, and antitumor antibiotic of high molecular weight. J Antibiot (Tokyo) [A] 18:63–76

  8. 8.

    Kawai Y, Katoh A (1972) Differential inhibition of DNA and RNA synthesis by neocarzinostatin in cultured Burkitt lymphoma cells. JNCI 48:1535–1538

  9. 9.

    Kramer WG, Feldman S, Broughton A, Strong JE, Hall SW, Holoye PY (1978) The pharmacokinetics of bleomycin in man. J Clin Pharmacol 18:346–352

  10. 10.

    Kumagi K, Koide T, Kikuchi M, Ishida N (1970) Specific inhibition of the initiation of DNA synthesis in HeLa cells by neocarzinostatin. Int Cancer Congr Abstr 10:401

  11. 11.

    Lowenthal I, Parker LM (1977) In vivo distribution of I125 neocarzinostatin (NCS) in tumor-bearing animals. Proc Am Assoc Cancer Res 18:124

  12. 12.

    Maeda H, Kumagi K, Ishida N (1966) Characterization of neocarzinostatin. J Antibiot (Tokyo) [A] 19:253–259

  13. 13.

    McKelvey EM, Burgess MA, McCredie KB, Bodey GP (1978) Neocarzinostatin: A phase I clinical trial. Proc Am Assoc Cancer Res 19:186

  14. 14.

    Ono, Y, Wataube Y, Ishida N (1966) Mode of action of neocarzinostatin: Inhibition of DNA synthesis and degradation of DNA in Sarcina lutea. Biochim Biophys Acta 119:46–58

  15. 15.

    Sakamoto K, Endo N, Sakka M (1973) Effect of neocarzinostatin on V-79 Chinese hamster cells in vitro. Eur J Cancer 9:725–728

  16. 16.

    Samy RS, Raso V (1980) Radioimmunoassay of neocarzinostatin, an antitumor protein. Cancer Res 36:4378–4381

  17. 17.

    Tobey RA (1972) A simple rapid technique for determination of the effects of chemotherapeutic agents on mammalian cell cycle traverse. Cancer Res 309–315

Download references

Author information

Correspondence to Stephen W. Hall.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Hall, S.W., Knight, J., Broughton, A. et al. Clinical pharmacology of the anticancer polypeptide neocarzinostatin. Cancer Chemother. Pharmacol. 10, 200–204 (1983). https://doi.org/10.1007/BF00255763

Download citation

Keywords

  • Liver Disease
  • Clinical Pharmacology
  • Drug Clearance
  • Plasma Decay
  • Marked Liver